Human breast cancer cells harboring a gatekeeper T798M mutation in HER2 overexpress EGFR ligands and are sensitive to dual inhibition of EGFR and HER2

PURPOSE: Mutations in receptor tyrosine kinase (RTK) genes can confer resistance to receptor-targeted therapies. A T798M mutation in the HER2 oncogene has been shown to confer resistance to the tyrosine kinase inhibitor (TKI) lapatinib. We studied the mechanisms of HER2-T798M-induced resistance to i...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Rexer, Brent N., Ghosh, Ritwik, Narasanna, Archana, Estrada, Mónica Valeria, Chakrabarty, Anindita, Song, Youngchul, Engelman, Jeffrey A., Arteaga, Carlos L.
Médium: Artigo
Jazyk:Inglês
Vydáno: 2013
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3809918/
https://ncbi.nlm.nih.gov/pubmed/23948973
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-13-1038
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky